BACE Fundamental Analysis - BRIGADE-M3 EUROPEAN ACQUIS-A

Fundamental Rating

BACE gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. BACE has a bad profitability rating. Also its financial health evaluation is rather negative. BACE does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year BACE was profitable.

1.2 Ratios

		Industry Rank	Sector Rank
ROA	0.5%
ROE	24.82%
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BACE so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

2.2 Solvency

An Altman-Z score of 1.89 indicates that BACE is not a great score, but indicates only limited risk for bankruptcy at the moment.

A Debt/Equity ratio of 47.13 is on the high side and indicates that BACE has dependencies on debt financing.

		Industry Rank	Sector Rank
Debt/Equity	47.13
Debt/FCF	N/A
Altman-Z	1.89

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

BACE has a Current Ratio of 35.22. This indicates that BACE is financially healthy and has no problem in meeting its short term obligations.

BACE has a Quick Ratio of 35.22. This indicates that BACE is financially healthy and has no problem in meeting its short term obligations.

		Industry Rank	Sector Rank
Current Ratio	35.22
Quick Ratio	35.22

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

EPS 1Y (TTM)N/A

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 55.56, which means the current valuation is very expensive for BACE.

The average S&P500 Price/Earnings ratio is at 26.50. BACE is valued rather expensively when compared to this.

		Industry Rank	Sector Rank
PE	55.56
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for BACE!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BRIGADE-M3 EUROPEAN ACQUIS-A

AMS:BACE (3/14/2023, 7:00:00 PM)

+0.1 (+1.01%)

Chartmill FA Rating

GICS SectorN/A

GICS IndustryGroupN/A

GICS IndustryN/A

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst OwnersN/A

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap287.50M

Revenue(TTM)N/A

Net Income(TTM)1.28M

AnalystsN/A

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr YearsN/A

Div Non Decr YearsN/A

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	55.56
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	60.07
P/tB	60.07
EV/EBITDA	N/A

EPS(TTM)0.18

EY1.8%

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)N/A

FCFYN/A

OCF(TTM)N/A

OCFYN/A

SpS0

BVpS0.17

TBVpS0.17

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	0.5%
ROE	24.82%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score1

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	47.13
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	35.22
Quick Ratio	35.22
Altman-Z	1.89

F-Score1

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)N/A

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1YN/A

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1YN/A

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1YN/A

OCF growth 3YN/A

OCF growth 5YN/A

BRIGADE-M3 EUROPEAN ACQUIS-A / BACE.AS FAQ

What is the ChartMill fundamental rating of BRIGADE-M3 EUROPEAN ACQUIS-A (BACE.AS) stock?

ChartMill assigns a fundamental rating of 1 / 10 to BACE.AS.

What is the valuation status for BACE stock?

ChartMill assigns a valuation rating of 0 / 10 to BRIGADE-M3 EUROPEAN ACQUIS-A (BACE.AS). This can be considered as Overvalued.

Can you provide the profitability details for BRIGADE-M3 EUROPEAN ACQUIS-A?

BRIGADE-M3 EUROPEAN ACQUIS-A (BACE.AS) has a profitability rating of 0 / 10.

What is the financial health of BRIGADE-M3 EUROPEAN ACQUIS-A (BACE.AS) stock?

The financial health rating of BRIGADE-M3 EUROPEAN ACQUIS-A (BACE.AS) is 2 / 10.

BRIGADE-M3 EUROPEAN ACQUIS-A (BACE.AS) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

BRIGADE-M3 EUROPEAN ACQUIS-A / BACE.AS FAQ

What is the ChartMill fundamental rating of BRIGADE-M3 EUROPEAN ACQUIS-A (BACE.AS) stock?

What is the valuation status for BACE stock?

Can you provide the profitability details for BRIGADE-M3 EUROPEAN ACQUIS-A?

What is the financial health of BRIGADE-M3 EUROPEAN ACQUIS-A (BACE.AS) stock?